by Coco Davis/ Fred Hutchinson Cancer Research Center
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy among women in the United States (US). Although the incidence rate is higher among White women, Black women have the lower survival … Read more
by Lindsey Fischer
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
Patients with ovarian cancer treated with FDA-approved
by the ASCO Post Staff
Today, 1 year after its founding, Break Through Cancer announced $50 million in grants to support several cutting-edge research projects using a novel “TeamLab” structure—designed to maximize interdisciplinary collaboration among researchers at Dana-Farber Cancer Institute, … Read more
by Charles Bankhead
— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk
The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more
by Jennifer Southall
Women with mitogen-activated protein kinase-mutated low-grade serous ovarian/peritoneal carcinoma experienced significantly longer PFS and OS compared with women without these mutations, according to study results.
The findings, presented during the Society of Gynecologic Oncology 2022 Annual … Read more
Approach can help radiologists in a busy clinical practice assess lesions more quickly
The appearance of ovarian lesions on ultrasound is an effective predictor of cancer risk that can help women avoid unnecessary surgery, according to a new study published … Read more
by Jonathan Goodman, MPhil
Hispanic and Non-Hispanic Black patients were significantly underrepresented, but Asian/Pacific Islander patients were overrepresented.
Clinical trials of PARP inhibitors in patients with ovarian cancer do not accurately reflect the racial and ethnic makeup of the real-world … Read more
by Monica Janke, MD
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved
by Jon Kelvey
Black patients with ovarian cancer were less likely than their White counterparts to receive adjuvant chemotherapy after primary surgery, according to a study published in Gynecologic Oncology.
The study also showed that patients who did not undergo … Read more
Blood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more
By Krista Conger
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
Women newly diagnosed with breast or ovarian cancer who are also … Read more
By The ASCO Post Staff
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely … Read more
By Ariana Pelosci
Women with gynecologic cancer who experience an improvement of social needs such as companionship and food insecurity could experience improved outcomes.
The identification of social needs and accompanying solutions could result in more actionable health care disparities … Read more
CAMBRIDGE, England — Virtual biopsies could replace invasive tissue procedures and give more accurate results thanks to a revolutionary new method developed using computer scans. The new advanced computing technique uses routine medical scans to enable doctors to take fewer, … Read more
By Professor Ian Jacobs
I was motivated to improve the outcome for women with ovarian cancer by my experience as a junior doctor in London in 1985. But 36 years on, the results aren’t what we’d hoped.
My colleages’ and
… Read moreBy Pam Harrison
Results from a huge British trial that involved more than 200,000 women who were followed for a median of 16 years have turned out negative. Investigators found that annual screening for ovarian cancer with either multimodal screening … Read more
Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study.
By Charles Bankhead
Two drugs outperformed one for hyperthermic intraperitoneal chemotherapy (HIPEC) after interval surgical debulking of advanced ovarian cancer, data from a prospective registry showed.
Median progression-free survival (PFS) doubled … Read more
The study finally paves the way for the use of antibodies different from IgG as immunotherapeutic agents for at least tumors currently resistant to conventional immune checkpoint blockade.
The prognosis of ovarian cancer is poor, with an estimated five-year survival … Read more
A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge. This is an important step towards precision tissue sampling for
